TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck reported that their personalized mRNA vaccine, intismeran, combined with Keytruda reduced the relative risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo. At two years, 82% of the vaccine combination group were alive without recurrence, compared with 70% of the control group. The reported results are from a Phase 3 trial; further detail on the data and next steps remains pending.
Moderna and Merck said their personalized mRNA cancer vaccine, intismeran, combined with Keytruda reduced the relative risk of melanoma recurrence or death by 42% over two years in a Phase 3 trial, compared with Keytruda plus placebo. The companies’ announcement describes results for patients whose melanoma had been surgically removed, a setting where treatment aims to lower the chance that cancer returns.
At the two-year assessment, 82% of patients who received intismeran with Keytruda were alive without recurrence, compared with 70% of those receiving Keytruda and placebo, according to the results summarized by Ars Technica from the companies’ announcement. The 42% figure refers to a relative reduction in the risk of recurrence or death, not a 42-percentage-point increase in the share of patients free of recurrence.
The vaccine combination also reduced the relative risk of distant metastasis or death by 38% compared with the control group. Distant metastasis means cancer has spread to a part of the body away from where it began. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, versus 80% of the Keytruda-placebo group.
The trial measured recurrence-free survival, or time without cancer returning, and distant metastasis-free survival, or time without cancer returning at a distant site. These are different outcomes from overall survival. The supplied report does not give an overall-survival result, detailed adverse-event figures, or the full statistical analysis of the Phase 3 findings.
A New Option After Melanoma Surgery
The results point to a potential addition to adjuvant treatment—therapy given after surgery to reduce the chance that cancer returns. The comparison is against Keytruda, an established treatment, rather than against no treatment. If the findings are confirmed in the complete trial data and the vaccine is authorized, the approach could give some patients an additional treatment option alongside standard immunotherapy.
The absolute difference reported at two years was 12 percentage points in the proportion alive without recurrence: 82% versus 70%. That offers a more direct view of the trial result than the relative-risk figure alone. It does not, by itself, show how an individual patient would fare, and the reported outcomes do not establish that the vaccine cures melanoma or improves overall survival.
Personalized production is also relevant to how this treatment might be delivered. Each vaccine is designed around mutations identified in an individual patient’s tumor, so manufacturing and treatment logistics differ from those for a standard, off-the-shelf drug. The supplied information does not specify production time, access, cost, or how these factors affected trial participation.
Products Worth Considering
OMRON VIVA 360+ Body Composition Monitor and Smart Scale
Withings Body Smart Wi-Fi and Bluetooth Smart Scale
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
As an affiliate, we earn on qualifying purchases.
How the Personalized Vaccine Works
Intismeran, also called mRNA-4157, is designed using genetic information from a patient’s tumor. Researchers compare the cancer’s genetic sequence with healthy cells, select cancer-specific mutations, and use synthetic mRNA to encode targets based on as many as 34 mutations. The intended effect is to prompt an immune response against cells carrying those tumor-specific features.
In the trial, the vaccine was given with Keytruda (pembrolizumab), Merck’s immunotherapy. The comparison group received Keytruda with placebo, allowing the companies to assess the added contribution of the personalized vaccine on top of that treatment. The report describes the participants as having resected melanoma, meaning their tumors had been removed surgically.
The new Phase 3 findings follow a five-year Phase 2 trial cited in the source report. That earlier study showed a 49% reduction in the relative risk of recurrence or death and a 59% reduction in the relative risk of distant metastasis or death. The Phase 3 figures reported so far are smaller, and differences between trials mean the results should not be treated as a direct head-to-head comparison.
“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””
— Dean Li, president of Merck Research Laboratories
Full Trial Data Still Pending
The reported figures are based on a company announcement summarized by Ars Technica. The supplied material does not include the full Phase 3 publication, the number of participants, confidence intervals, statistical significance details, or a complete account of side effects. Those details are needed to assess the strength and limits of the findings.
It is also unclear from the available information how long patients will be followed, whether the advantage persists beyond the reported two-year assessment, and whether the combination changes overall survival. The reported reductions concern recurrence-related and metastasis-related outcomes, each combined with death as an endpoint; they should not be described as a demonstrated reduction in death alone.
The 42% relative-risk reduction does not mean that 42% more patients avoided recurrence. The reported two-year recurrence-free proportions were 82% and 70%. Individual benefit may vary, and the results do not establish which patient groups are most likely to benefit.
Publication and Regulatory Steps Ahead
The next key steps are release of the complete Phase 3 results and independent review of the trial data, including safety findings and the statistical analysis. The companies’ announcement, as described in the source material, does not establish an approval decision or provide a timetable for one.
Any regulatory application would be assessed by the relevant health authorities before the vaccine could be routinely prescribed for this use. Until fuller data and regulatory decisions are available, intismeran should be described as an investigational personalized vaccine, rather than an approved melanoma treatment. Patients should discuss treatment choices with their oncology team.
Key Questions
What did the trial find?
The companies reported that intismeran plus Keytruda reduced the relative risk of melanoma recurrence or death by 42% over two years compared with Keytruda plus placebo. At two years, 82% of the combination group were alive without recurrence, versus 70% of the control group.
Does the 42% figure mean deaths fell by 42%?
No. The reported 42% applies to the combined outcome of recurrence or death. The source material does not report a separate overall-survival result, so it does not establish that deaths alone fell by 42%.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed from mutations identified in a patient’s tumor. In the reported trial it was given with Merck’s immunotherapy Keytruda.
Is the vaccine approved for melanoma?
The supplied material reports trial results but does not say that intismeran has received regulatory approval for this use. The full data and any regulatory review remain important next steps.
What information is still missing?
The available report does not provide the full trial publication, participant numbers, detailed safety results, statistical intervals, or an overall-survival finding. Longer follow-up will also help show whether the reported benefits persist.
Source: hn
